Post by
bligicka on Feb 01, 2021 8:39am
Patent news !!!
The Company further advises that it has successfully obtained a European patent for its anticancer antibody platform - European Patent EP2756307B1 entitled “Antibodies directed against signal peptides, methods and uses thereof”. This granted patent provides broad patent protection for an antibody for use in the treatment of a MUC1 expressing cancer, as well as for an ex vivo method of diagnosing cancer in a subject and an ex vivo method for determining the suitability for treatment of a subject suffering from a MUC1 expressing cancer. Kits for practicing these methods are also included. This patent strengthens Vaxil Bio’s broad patent coverage with regards to its proprietary anti-cancer and anti-pathogenic portfolio.
Comment by
Grills on Feb 01, 2021 8:49am
just what we needed to hear $$$$$$$$$$$$$$$$$$$$$$$$$$%